Research programme: vaccines - CyTuVax
Alternative Names: PanCaVaxLatest Information Update: 28 Aug 2025
At a glance
- Originator CyTuVax
- Class Vaccines
- Mechanism of Action Immunogenetic stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Pancreatic cancer
- Discontinued Cytomegalovirus infections
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Malignant-melanoma in Netherlands
- 28 Aug 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer in Netherlands
- 25 Aug 2023 Preclinical development in Pancreatic-cancer and Malignant melanoma still ongoing